Free Trial

Running Oak Capital LLC Grows Position in STERIS plc (NYSE:STE)

STERIS logo with Medical background

Running Oak Capital LLC increased its position in STERIS plc (NYSE:STE - Free Report) by 13.3% in the first quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 46,145 shares of the medical equipment provider's stock after purchasing an additional 5,407 shares during the quarter. Running Oak Capital LLC's holdings in STERIS were worth $10,374,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other institutional investors and hedge funds also recently made changes to their positions in the company. Vanguard Group Inc. lifted its stake in shares of STERIS by 0.5% in the 4th quarter. Vanguard Group Inc. now owns 11,864,606 shares of the medical equipment provider's stock valued at $2,608,434,000 after purchasing an additional 53,526 shares during the period. Massachusetts Financial Services Co. MA increased its position in STERIS by 1.3% during the 4th quarter. Massachusetts Financial Services Co. MA now owns 5,811,818 shares of the medical equipment provider's stock valued at $1,277,728,000 after buying an additional 77,152 shares in the last quarter. Northern Trust Corp increased its position in STERIS by 0.5% during the 3rd quarter. Northern Trust Corp now owns 1,218,012 shares of the medical equipment provider's stock valued at $267,256,000 after buying an additional 6,101 shares in the last quarter. Norges Bank bought a new position in STERIS during the 4th quarter valued at approximately $220,954,000. Finally, Mitsubishi UFJ Asset Management Co. Ltd. increased its position in STERIS by 4.8% during the 4th quarter. Mitsubishi UFJ Asset Management Co. Ltd. now owns 976,402 shares of the medical equipment provider's stock valued at $208,491,000 after buying an additional 44,781 shares in the last quarter. Hedge funds and other institutional investors own 94.69% of the company's stock.

Insider Buying and Selling

In related news, VP Renato Tamaro sold 1,154 shares of STERIS stock in a transaction on Thursday, May 16th. The stock was sold at an average price of $231.64, for a total transaction of $267,312.56. Following the transaction, the vice president now directly owns 6,677 shares in the company, valued at $1,546,660.28. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. In related news, Director Jacqueline B. Kosecoff sold 4,584 shares of STERIS stock in a transaction on Monday, May 13th. The stock was sold at an average price of $231.53, for a total transaction of $1,061,333.52. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Also, VP Renato Tamaro sold 1,154 shares of STERIS stock in a transaction on Thursday, May 16th. The shares were sold at an average price of $231.64, for a total value of $267,312.56. Following the transaction, the vice president now owns 6,677 shares in the company, valued at $1,546,660.28. The disclosure for this sale can be found here. Insiders sold 7,762 shares of company stock valued at $1,798,477 over the last 90 days. Company insiders own 1.14% of the company's stock.

Wall Street Analysts Forecast Growth

STE has been the subject of a number of analyst reports. Piper Sandler reaffirmed a "neutral" rating and set a $225.00 price objective (up previously from $220.00) on shares of STERIS in a research report on Friday, May 10th. StockNews.com raised STERIS from a "hold" rating to a "buy" rating in a report on Saturday, June 15th. Needham & Company LLC reissued a "hold" rating on shares of STERIS in a report on Friday, May 10th. Finally, JMP Securities reissued a "market outperform" rating and issued a $265.00 target price on shares of STERIS in a report on Thursday, May 9th. Three equities research analysts have rated the stock with a hold rating and four have given a buy rating to the company's stock. According to MarketBeat, the company has an average rating of "Moderate Buy" and a consensus target price of $241.60.


Read Our Latest Analysis on STE

STERIS Stock Performance

Shares of STE traded down $1.19 during trading hours on Friday, hitting $218.12. The stock had a trading volume of 832,075 shares, compared to its average volume of 445,017. The company has a debt-to-equity ratio of 0.49, a current ratio of 3.08 and a quick ratio of 2.36. STERIS plc has a 12 month low of $195.47 and a 12 month high of $254.00. The firm has a market capitalization of $21.56 billion, a PE ratio of 57.10 and a beta of 0.85. The stock has a fifty day moving average price of $218.42 and a 200 day moving average price of $220.53.

STERIS (NYSE:STE - Get Free Report) last issued its quarterly earnings data on Wednesday, May 8th. The medical equipment provider reported $2.58 EPS for the quarter, topping the consensus estimate of $2.41 by $0.17. STERIS had a return on equity of 13.73% and a net margin of 6.95%. The company had revenue of $1.42 billion during the quarter, compared to analyst estimates of $1.41 billion. During the same quarter in the previous year, the company posted $2.30 earnings per share. STERIS's revenue was up 10.8% compared to the same quarter last year. Analysts anticipate that STERIS plc will post 9.24 EPS for the current year.

STERIS Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Wednesday, June 26th. Investors of record on Wednesday, June 12th will be issued a $0.52 dividend. This represents a $2.08 annualized dividend and a dividend yield of 0.95%. The ex-dividend date is Wednesday, June 12th. STERIS's payout ratio is currently 54.45%.

STERIS Profile

(Free Report)

STERIS plc provides infection prevention products and services worldwide. It operates through four segments: Healthcare, Applied Sterilization Technologies, Life Sciences, and Dental. The Healthcare segment offers cleaning chemistries and sterility assurance products; automated endoscope reprocessing system and tracking products; endoscopy accessories, washers, sterilizers, and other pieces of capital equipment for the operation of a sterile processing department; and equipment used directly in the operating room, including surgical tables, lights, and connectivity solutions, as well as equipment management services.

Read More

Institutional Ownership by Quarter for STERIS (NYSE:STE)

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.

Should you invest $1,000 in STERIS right now?

Before you consider STERIS, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and STERIS wasn't on the list.

While STERIS currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

Beginners Guide To Retirement Stocks Cover

Click the link below and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio.

Get This Free Report
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Opportunities Arise as Stock Market Rotates from Big Tech
3 Top Market Leaders Splitting Their Stocks
How to Navigate Stock Downgrades

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines